Medical device sales remained a bright spot for the company, however, with more than 20% growth in diabetes devices.

Abbott warned on Thursday it expects more than $1 billion in financial headwinds this year from a sharp decline in COVID-19 testing demand, new U.S. tariffs, and the government's foreign aid freeze.

The Food and Drug Administration issued on Wednesday an emergency use authorization to the Abbott BinaxNOW COVID-19 Ag Card Point of Care SARS-CoV-2 test, which can provide results within 15 ...

Abbott has signed a contract to supply HHS with 30 million additional tests through March, according to CNBC. The BinaxNOW test is the size of a credit card, costs $5 and gives results in 15 minutes.

The company told NPR in December the cost would be $30 per test. Abbott's BinaxNOW tests have been available since August, and Abbott produces 50 million of these tests each month.

Abbott received the FDA’s emergency use authorization clearance for its rapid COVID-19 detection test BinaxNOW COVID-19 Ag Card. 1. Abbott will sell the test for $5. 2. The test is the size of a ...

Abbott's BinaxNOW rapid COVID-19 test is seen in the photo. The Food and Drug Administration authorized Abbott's BinaxNow and Quidel's QuickVue tests to be sold without a prescription for ...

When Abbott Laboratories asked the FDA to approve BinaxNOW, for example, the company had performed the test on 460 people exhibiting symptoms. Only 17 of them were between 6 and 21 years old.